Compensation award — excluded from discretionary-purchase analysis.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell
View the official recordSEC Form 4 — Statement of Changes in Beneficial OwnershipAll the details
Dates, kept separate
Transaction date
May 15, 2026
Reporting period
Not applicable
Filed with the SEC
May 19, 2026
OfficerGrant / award
Context
Classification
grant award
Code A — grant or award
Planned / mechanical clue
Footnote references an employee stock purchase plan
Only flagged when a footnote says so; never inferred
Source receipt
Record ID
0000313143-26-000044
Filed / recorded
May 19, 2026, 9:31 PM UTC
Added to OQRO
Oct 6, 2026, 7:59 PM UTC
Parser
form4-xml-v2
Data quality
Verified: identifiers matched exactly
Issuer
HAEMONETICS CORP
Issuer CIK
313143
Ticker
HAE
Reporting person
Roy Galvin
Relationship
Officer
Officer title
EVP, Chief Commercial Officer
Security
Common Stock
Table
Non-derivative (Table I)
Transaction date
May 15, 2026
Transaction code
A
Shares / units
27,535
Acquired / disposed
Acquired (A)
Shares owned after
39,882
Ownership form
Direct
Amendment
No
Footnotes from the filing
The securities awarded are in the form of RSUs issued pursuant to the Haemonetics Corporation Amended and Restated 2019 Long-Term Incentive Compensation Plan. The RSUs vest in three annual installments with forty percent of the total award vesting on the first anniversary of the date of grant, forty percent vesting on the second anniversary of the date of grant and the remaining twenty percent vesting on the third anniversary of the date of grant.
Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested.
This number includes unvested RSUs previously reported as well as 415 shares acquired by the reporting person under the Haemonetics Corporation 2007 Employee Stock Purchase Plan (as amended and/or restated from time to time) on April 30, 2026.
